氟喹诺酮类药物治疗耐多药结核病临床疗效研究  

Fluoro-quinolones in the Treatment of MDR-TB Clinical Efficacy Studies

作　　者：童海娟[1] 程毅[1] 谭川[1] 

机构地区：[1]达州市疾病预防控制中心,四川达州635000

出　　处：《中国伤残医学》2013年第7期48-49,共2页Chinese Journal of Trauma and Disability Medicine

摘　　要：目的:观察和评价氟喹诺酮类药物结合一、二线抗TB药物治疗耐多药结核病(MDR-TB)临床有效性及安全性。方法:将156例MDR-TB患者随机分为2组,其中观察组采用6MfxZPtoKmPAS/18MfxZPtoPAS(莫西沙星+吡嗪酰胺+丙硫异烟胺+卡那霉素+对氨基水杨酸)化疗方案;对照组采用6LfxZPtoKmPAS/18LfxZPtoPAS(左氧氟沙星+吡嗪酰胺+丙硫异烟胺+卡那霉素+对氨基水杨酸)化疗方案。疗程24个月。结果:2组疗程完成后,观察组79例患者显效62例,总有效率为96.20%,对照组77例患者显效49例,总有效率为84.42%,2组临床疗效比较差异有显著性(P<0.01),而观察组患者3个月、12个月痰菌阴转率分别为55.69%,73.42%,24个月疗程结束时累计有68例患者痰菌阴转,阴转率为86.08%,均高于对照组,且差异显著有统计学意义(P<0.05),观察组不良反应发生率为16.46%(13/79);对照组为15.58%(12/77),2组比较差异无统计学意义(P>0.05)。结论:氟喹诺酮类药物结合一、二线抗TB药物治疗耐多药结核病(MDR-TB)临床无交叉耐药性,疗效显著,且有较高安全性。Objective： Observation and evaluation of fluoroquinolones in combination with a one second - line anti - TB drugs to treat multidrug- resistant tuberculosis （MDR- TB） Clinical efficacy and safety. Methods ：156 cases of MDR- TB patients were randomly di- vided into two groups, in which the observation group adopted 6MfxZPtoKmPAS/18MfxZPtoPAS Chemotherapy; Controlgroupdopted6LfxZPtoKmPAS/18LfxZPtoPAS chemotherapy, Treatment for 24 months. Results： Observation group of 79 patients, 62 cases had marked effect, total effective rate was 96.20%, Control group 77 patients in 49 cases had marked effect, total effective rate was 84.42%, Comparison of clinical efficacy difference was significant（ P 〈 0. O1 ）, Observation group the patients 3 months, 12 months spu- tum negative rate were 55.69% , 73.42% , 24 months of treatment at the end of the cumulative sputum negative rate 68patients, sputum negative rate were 86.08%, Significantly higher than that of the control group, and the difference was statistically significant（ P 〈 0.05 ）, Observation group the incidence of adverse reactions was 16.46% （13/79） ; The control group was 15.58% （ 12/77）, The difference between the two groups was not statistically significant （ P 〉 0.05 ）. Conclusion： fluoroquinolones in combination with a one second - line anti -TB drugs to treat multidrug -resistant tuberculosis （MDR -TB） Clinical No cross resistance in curative effect is distinct, and has higher security.

关 键 词：氟喹诺酮类药物 莫西沙星 左氧氟沙星 耐多药结核病 化疗方案 疗效 

分 类 号：R52[医药卫生—内科学]